|
JPH10130258A
(ja)
*
|
1996-10-10 |
1998-05-19 |
Eli Lilly & Co |
ベンゾ［ｂ］チオフェン化合物、中間体、製剤、および方法
|
|
WO1998048794A1
(en)
*
|
1997-04-30 |
1998-11-05 |
Eli Lilly And Company |
Antithrombotic agents
|
|
US6172100B1
(en)
|
1997-04-30 |
2001-01-09 |
Eli Lilly And Company |
Antithrombotic agents
|
|
ATE268768T1
(de)
*
|
1997-04-30 |
2004-06-15 |
Lilly Co Eli |
Antithrombosemittel
|
|
WO1998049161A1
(en)
|
1997-04-30 |
1998-11-05 |
Eli Lilly And Company |
Antithrombotic agents
|
|
WO1998048804A1
(en)
|
1997-04-30 |
1998-11-05 |
Eli Lilly And Company |
Antithrombotic agents
|
|
US6541499B1
(en)
|
1997-05-01 |
2003-04-01 |
Eli Lilly And Company |
Antithrombotic agents
|
|
CA2291026A1
(en)
|
1997-06-05 |
1998-12-10 |
Takeda Chemical Industries, Ltd. |
Heterocyclic compounds, their production and use
|
|
US6017914A
(en)
*
|
1997-09-03 |
2000-01-25 |
Eli Lilly And Company |
Benzo[b]thiophene compounds, intermediates, formulations, and methods
|
|
US6284756B1
(en)
|
1998-04-30 |
2001-09-04 |
Eli Lilly And Company |
Antithrombotic agents
|
|
US6166069A
(en)
*
|
1998-05-12 |
2000-12-26 |
American Home Products Corporation |
Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
|
|
DK0997460T3
(da)
*
|
1998-10-28 |
2003-03-31 |
Lilly Co Eli |
Benzothiophenforbindelser som antithrombotiske midler og mellemprodukter
|
|
ES2213984T3
(es)
|
1998-10-30 |
2004-09-01 |
Eli Lilly And Company |
Derivados de azaindol y su uso como agentes antitrombicos.
|
|
WO2001036414A1
(en)
*
|
1999-11-19 |
2001-05-25 |
Eli Lilly And Company |
Antithrombotic agents
|
|
ES2236536T3
(es)
|
2001-05-22 |
2005-07-16 |
Eli Lilly And Company |
Derivados tetrahidroquinolino para la inhibicion de enfermedades asociadas con la privacion de estrogenos o con una respuesta fisiologica aberrante a estrogenos endogenos.
|
|
ATE321754T1
(de)
|
2001-05-22 |
2006-04-15 |
Lilly Co Eli |
2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
|
|
WO2003059884A1
(en)
|
2001-12-21 |
2003-07-24 |
X-Ceptor Therapeutics, Inc. |
Modulators of lxr
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
ATE433322T1
(de)
*
|
2002-07-22 |
2009-06-15 |
Lilly Co Eli |
Selektive östrogenrezeptor modulatoren, die eine phenylsulfonyl-gruppe enthalten
|
|
WO2005011751A2
(en)
*
|
2003-07-31 |
2005-02-10 |
University Of Pittsburgh |
Measuring device and method of measuring
|
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
|
LT2896397T
(lt)
|
2003-08-01 |
2017-11-27 |
Mitsubishi Tanabe Pharma Corporation |
Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
|
|
US8278290B2
(en)
|
2005-02-14 |
2012-10-02 |
Biononics Limited |
Tubulin polymerisation inhibitors
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
UY30730A1
(es)
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
|
MX2010002695A
(es)
|
2007-09-10 |
2010-04-01 |
Janssen Pharmaceutica Nv |
Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt).
|
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
SI2488515T1
(sl)
|
2009-10-14 |
2017-04-26 |
Janssen Pharmaceutica Nv |
Postopek za pripravo spojin, ki so uporabne kot inhibitorji SGLT2
|
|
TWI599360B
(zh)
|
2010-05-11 |
2017-09-21 |
健生藥品公司 |
醫藥調配物
|
|
RS55056B1
(sr)
|
2011-04-13 |
2016-12-30 |
Janssen Pharmaceutica Nv |
Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
|
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
|
|
WO2013087647A1
(en)
|
2011-12-15 |
2013-06-20 |
Bayer Intellectual Property Gmbh |
Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer
|
|
EP2817311B1
(en)
|
2012-02-23 |
2016-04-06 |
Bayer Intellectual Property GmbH |
Substituted benzothienyl-pyrrolotriazines and uses thereof
|
|
US10308871B2
(en)
|
2015-02-19 |
2019-06-04 |
Jnc Corporation |
Liquid crystal compound having benzothiophene, liquid crystal composition and liquid crystal display device
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
EA202092441A1
(ru)
|
2016-06-07 |
2021-05-21 |
Джакобио Фармасьютикалс Ко., Лтд. |
Новые гетероциклические производные, применимые в качестве ингибиторов shp2
|
|
KR20240026521A
(ko)
|
2017-03-23 |
2024-02-28 |
자코바이오 파마슈티칼스 컴퍼니 리미티드 |
Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
|
|
CN112839935A
(zh)
|
2018-09-26 |
2021-05-25 |
北京加科思新药研发有限公司 |
可用作shp2抑制剂的新型杂环衍生物
|